MedTrace Logo

Identification of Kinematic Variables Specific of Patellar Tendinopathy in Athletes at Risk

NCT07406516 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-02-12

No results posted yet for this study

Summary

This research aims to identify and monitor specific kinematic markers associated with patellar tendinopathy in athletes at risk. Using a markerless motion capture system, vertical jump tests will be analyzed to detect early biomechanical changes in the knees, hips, trunk, and ankles. By comparing injured participants, the study seeks to improve early diagnosis and personalized prevention strategies for patellar tendinopathy.

Conditions

  • Patellar Tendinitis
  • Jumper's Knee
  • Musculoskeletal Injuries
  • Knee Injuries

Interventions

DIAGNOSTIC_TEST

The intervention consists of a series of vertical jump tests captured using high-resolution cameras with markerless motion capture technology.

Participants will undergo clinical evaluations including the Single Leg Decline Squat (SLDS) test, VISA-PF, OSTRC-P questionnaires, and Doppler ultrasound of the patellar tendon. These assessments will take place at baseline (T0) and follow-up periods (M3, M6, M9, M12) to track the evolution of kinematic markers and clinical symptoms related to patellar tendinopathy.

DIAGNOSTIC_TEST

The intervention consists of a series of vertical jump tests captured using high-resolution cameras with markerless motion capture technology at 6 months and 12 months

Participants will undergo clinical evaluations including the Single Leg Decline Squat (SLDS) test, VISA-PF, OSTRC-P questionnaires, and Doppler ultrasound of the patellar tendon. These assessments will take place at baseline (T0) and follow-up periods ( M6 et M12) to track the evolution of kinematic markers and clinical symptoms related to patellar tendinopathy.

Sponsors & Collaborators

  • University Hospital, Montpellier

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-05-01
Primary Completion
2029-05-01
Completion
2029-05-01

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07406516 on ClinicalTrials.gov